RxDoctor Payments DataLook up a doctor →

Hiren Shah, MD

Cardiovascular Disease · Columbus, GANPI 1437271426

Payments from drug & device makers

$166,494in general payments, 2019–2025

Across 623 payments — averaging $267.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$156K
  • Abbott$2K
  • Endologix LLC$2K
  • Johnson & Johnson$822
  • Novartis$565
  • Medtronic$529
  • plus $4K from 35 others

What the payments were for

  • Speaking & faculty fees$140,78085%
  • Travel & lodging$11,2787%
  • Food & beverage$14,4139%
  • Education$70%
  • Other$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$166,494 in reported general payments places this provider in the 90th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$960,168
Medicare patients
1,147
Services billed
10,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban373$329,233
Repatha SureclickEvolocumab162$160,541
XareltoRivaroxaban63$85,068
EntrestoSacubitril/Valsartan72$74,073
BrilintaTicagrelor70$50,728
JardianceEmpagliflozin58$46,952
Praluent PenAlirocumab40$20,727
FarxigaDapagliflozin Propanediol20$17,772
Ranolazine ErRanolazine159$15,813
ClopidogrelClopidogrel Bisulfate511$6,553
NexlizetBempedoic Acid/Ezetimibe12$5,695
Metoprolol Succinate271$3,760
Amiodarone Hcl90$2,875
Atorvastatin Calcium300$2,662
Rosuvastatin Calcium148$2,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$329,233373 claims
Johnson & JohnsonXarelto$822$85,06863 claims
NovartisEntresto$565$74,07372 claims
AstraZenecaBrilinta, Farxiga$284$68,50090 claims
Boehringer IngelheimJardiance$169$46,95258 claims
Esperion Therapeutics, Inc.Nexlizet$89$5,69512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →